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In addition to having antimicrobial properties, defensins inactivate various structurally unrelated bacterial
toxins by a yet unknown manner. In this issue of Immunity, Kudryashova et al. (2014b) provide insights
into mechanisms by which human a-defensins destabilize and inactivate bacterial toxins.The human innate immune system has
many effector molecules, which are able
to prevent or restrict pathogen invasion
and infection. Among these, a-defen-
sins—small, cationic, and amphipatic
peptides stored in either neutrophils
(neutrophil defensin 1 [HNP1]) or Paneth
cells (a-defensin 5 [HD5]) of the gut
mucosa—have broad-spectrum bacteri-
cidal activities with a preference against
gram-positive bacteria (Zhao and Lu,
2014). The antimicrobial mechanism of
a-defensins is mainly the disorganization
of bacterial membranes, causing pore
formation followed by cell disruption or
the formation of ‘‘nano nets.’’ Apart from
being bactericidal, defensins have anti-
viral properties; they also inactivate
bacterial toxins by showing little, if any,
toxicity for human proteins. But how
does the latter happen? This preference
of defensins for various structurally unre-
lated bacterial toxins is surprising, and
we do not have any plausible hypothesis
to explain it.
Defensins inhibit pore-forming choles-
terol-dependent cytolysins (CDCs; Lehrer
et al., 2009), which represent major
virulence factors produced by many
Gram-positive pathogens, such as Liste-
ria monocytogenes, Bacillus anthracis,
or Streptococcus pneumonia. In addition,
defensins inhibit diverse enzymatic toxins
from B. anthracis (Kim et al., 2006), Cory-
nebacterium diphtheria, Pseudomonas
aeruginosa,Clostridium difficile, or Staph-
ylococcus aureus. These bacterial toxins
represent a variety of structural and
enzymatic classes of proteins, making it
impossible for defensins to inactivate the
toxins on the basis of a specific activity
or structural element.
The fact that many seemingly unrelated
bacterial toxins are targeted by defensins
implies that these share some common
features that separate them from themajority of other proteins. In this issue of
Immunity, an elegant study by Kudrya-
shova et al. (2014b) contributes to our
understanding of toxin-inactivating innate
immune host responses. The authors
speculated that the elusive property
shared by many bacterial toxins is their
thermodynamic instability, which is the
low positive energy change for unfolding.
This property is linked to conformational
plasticity and is indispensable for the
toxin’s pore formation within membranes
and/or for the toxin to pass through a
narrow pore. To test this hypothesis, the
authors focused on the effector domains
of the thermodynamically unstable Vibrio
cholera multifunctional autoprocessing
repeats-in-toxin (MARTX) toxin (Kudrya-
shova et al., 2014a), which has to cross
a pore to reach the cytoplasmic domain
of a host cell. To investigate whether the
inhibitory activity of a-defensin HNP1
extends to MARTXVc toxin, the authors
assessed its effects on the autoprocess-
ing activity of MARTX cysteine protease
domain (CPDVc) and the catalytic activity
of the actin crosslinking domain (ACDVc).
In the presence of HNP1, the initial reac-
tion rate of actin crosslinking by ACDVc
was inhibited, whereas three tested
mammalian enzymes were not altered by
HNP1 under similar conditions. Next, the
authors investigated the proteolytic auto-
processing of a recombinant construct
containing all four MARTXVc domains
fused together in their natural orientation.
This was activated by an activator of
CPD, which led to a cleavage at the
well-defined interdomain linker regions
connecting the MARTXVc effector do-
mains. As one of the most remarkable
findings of this study, HNP1 changed
the character of cleavage in a way that
apparently inhibited autoprocessing.
CPD cleaved the exposed Leu residues
with low specificity for the adjacent aminoImmunity 41, Nacid content. This suggests that the total
protein reduction the authors found re-
sulted from cleavage at additional Leu
residues originally buried in the native
protein conformation and therefore inac-
cessible for cleavage by the cysteine
proteinase CPD. What emerges from
this study is that HNP1 promotes toxin
unfolding or misfolding and thus creates
conditions for the formation of randomly
fragmented polypeptides.
Another remarkable finding of this
study is that HNP1 affected stability and
proteolytic sensitivity of HNP1-sensitive
toxins, but not of HNP1-insensitive toxins
or mammalian proteins. Thus, the au-
thors’ findings support the idea that
HNP1 facilitates unfolding of susceptible
toxins (Figure 1). This increased level of
proteolytic susceptibility contributes to
our understanding of the mechanism by
which HNP1 inactivates bacterial toxins.
Additional support for the hypothesis
that HNP1 facilitates conformational
changes in bacterial toxins was elegantly
given with experiments using intrinsic
Trp fluorescence as a noninvasive re-
porter of conformational changes in a
protein. Higher accessibility of Trp resi-
dues to collisional quenchers is indicative
of a higher degree of protein unfolding. It
was found that Trp fluorescence of actin,
PLS3, and TcdA-GTD (the HNP1-insensi-
tive toxin homolog) was not affected by
HNP1. In contrast, ACDVc and TcdB-
GTD showed increased Trp fluorescence
in the presence of HNP1, indicative of
being more exposed to solvent and thus
conformational changes.
To investigate the stoichiometry of
HNP1-toxin interactions, the authors
probed interaction-mediated conforma-
tional changes by using ion mobility
mass spectrometry (IM-MS)—a new MS
method for analyzing conformational



















Figure 1. Mechanism of Bacterial Toxin Destabilization by HNP1
To enter the host cell cytoplasm, bacterial toxins need to cross the cellular membrane by forming a pore or
passing through a narrow pore. This process involves structural changes of the monomeric toxin, which
forms defined multimeric complexes necessary for membrane penetration. Critical structural elements
for the formation of accurate pores are hydrophobic sections of the toxinmolecule, which are in the resting
state buried deep in the molecule and exposed in a defined manner upon activation for accurate pore
formation. The toxin’s thermodynamic instability is tightly linked to a conformational plasticity indispens-
able for the formation of a membrane pore. In this issue of Immunity, Kudryashova et al. showed that
HNP1, a known toxin-inactivating peptide, forms a complex with the toxin and thereby exposes the toxin’s
buried hydrophobic sections. This results in the formation of insoluble aggregates and the exposure
of protease-sensitive areas of the toxin. As a consequence, the toxin now underlies limited proteolysis.
To this end, it does not allow the formation of membrane pores, leading to inactivation of the toxin.
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solvent exposure of hydrophobic residues
in the toxins, which would result in the
formation of complexes and toxin aggre-
gation. By IM-MS analyses, the results
led them to speculate that it was caused
by hydrophobic interaction between the
toxins and HNP1.
Structural perturbations caused by
binding to proteins can be identified by
a comparison of collisional cross section
values in IM-MS experiments with those
theoretically estimated. The authors
found that HNP1 treatment with actin did
not cause differences—in contrast to in-
vestigations with ACDVc and B. anthracis
protective antigen toxin—and concluded
that HNP1 binding causes ACDVc defor-
mation that can be best described as
partial, or local, unfolding. In agreement
with low thermodynamic stability, sur-
face-induced dissociation IM-MS experi-
ments revealed two distinct states—a
‘‘native’’ state and an ‘‘unfolded’’ state.
ACD-defensin complex activation re-
vealed only an unfolded state. Whereas
activation of PA led only to a relatively
more stable partially unfolded state, the672 Immunity 41, November 20, 2014 ª2014PA-defensin complex showed the pres-
ence of partially unfolded and deeply
unfolded states. These suggest that
HNP1 destabilizes both ACDVc and PA
but does not destabilize actin.
The authors elegantly showed by anal-
ysis of circular dicroism and differential
scanning fluorimetry (DSF) that destabili-
zation of ACDVc secondary and tertiary
structures occurred in the presence of
HNP1. A number of toxins, such as
anthrax toxin, TcdB, and CDC toxins,
were already recognized as defensin tar-
gets, but for others, such effects have
not been reported. Using the DSF
approach, investigations of these less
studied toxins showed that HNP1 pro-
moted denaturation of all toxin domains
except two, which are known to be resis-
tant toward HNP1 treatment. In striking
contrast, most of the mammalian struc-
tural proteins and enzymes were not
affected.
Are the author’s observations relevant
under physiological conditions of salt,
serum, and HNP1 concentrations? Ku-
dryashova et al. showed that cultured
normal intestinal epithelial cells were pro-Elsevier Inc.tected from toxin effects in the presence
of HNP1 at concentrations found in
plasma under severe infection conditions.
The only relevant HNP1-producing
cells are neutrophils, where this defensin
is located in azurophilic granules and
involved in the intracellular killing of
phagocytosed organisms (Lehrer and Lu,
2012). Thus, extracellular release of
HNP1 seems to be a rather rare event
happening mostly at severe inflammatory
conditions. This raises the question of
whether the human body has similar
toxin-inactivating innate defense mole-
cules for protective purposes, in particular
at gastrointestinal tract mucosal sur-
faces—places of initial contact of the
toxin-producing microbes. A candidate
innate defense factor is the enteric HD5,
which is constitutively secreted as pre-
cursor by Paneth cells of the gut epithe-
lium, where it is proteolytically cleaved
to the broad-spectrum antimicrobial
peptide HD5 (Ghosh et al., 2002). DSF
tests revealed that HD5—similar to
HNP1—also destabilized toxin compo-
nents and promoted its limited proteoly-
sis. Similarly, but to a lesser extent,
another epithelial antimicrobial peptide,
b-defensin 2 (Harder et al., 1997), destabi-
lized toxin components. These findings
suggest that unfolding of thermolabile
toxins is a general mechanism shared by
several defensins.
It is intriguing to speculate that possibly
other amphipathic antimicrobial peptides,
e.g., the cathelicidin LL37 or other epithe-
lial antimicrobial proteins, such as RNase
7 or the S100 proteins psoriasin and
calprotectin (S100A8/A9; Harder et al.,
2007), share this property of destabilizing
toxins. Moreover, other not-yet-recog-
nized amphipathic proteins, which have
no antimicrobial properties, might act
primarily as toxin-destabilizing innate de-
fense factors. Kudryashov et al.’s exciting
findings could, apart from possibly pre-
dicting destabilization- and limited-pro-
teolyse-sensitive toxins, promote the
development of novel, possibly also low-
molecular-weight toxin inactivators.REFERENCES
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T cell depletion can prevent hypertension in experimental animals. What is the nature of T cell activation in
hypertension? In this issue of Immunity, Carnevale et al. (2014) implicate PlGF signaling in a reservoir of
splenic T cells.Most immunologists do not list ‘‘hyperten-
sion’’ in their keywords. Scientists inter-
ested in immunity usually focus on he-
matopoietic cells, the cellular responses
to infection and products of sterile injury,
and the genetic mechanisms underlying
signal transduction. But there are notable
exceptions. The history of immunological
approaches to blood pressure has pro-
duced extremely impactful results.
One example is monoclonal anti-tumor
necrosis factor (TNF) antibody therapies,
now used by millions of autoimmune and
autoinflammatory disease patients. The
first experiments using monoclonal anti-
TNF antibodies as an experimental thera-
peutic agent were to prevent low blood
pressure (‘‘shock’’) in baboons infected
with lethal quantities of E. coli (Tracey
et al., 1987). Administration ofmonoclonal
anti-TNF prevented the drop in blood
pressure mediated by TNF. This insight
prompted the pharmaceutical manu-
facturing of TNF mAb. The availability of
these clinical reagents was pivotal to sub-
sequent clinical use in rheumatoid arthritis
and inflammatory bowel disease.
In the United States, 67 million adults,
many of them immunologists, have high
blood pressure. Hypertension is a contrib-
uting factor in the deaths of 350,000, with
an attributed nationwide cost basis
exceeding $45 billion, annually. Despite
the enormity of this health problem, themechanisms underlying hypertension are
at best incompletely understood. Under-
lying mechanisms for hypertension can
be established in only 10% of cases.
The remainder is classified as ‘‘essential
hypertension,’’ meaning chronically ele-
vated blood pressure from unknown
causes. Incomplete pathogenic knowl-
edge underlies the inadequate efficacy
of many, if not most, current therapies.
It certainly makes a compelling argu-
ment that new research approaches are
needed. Immunology research may open
the door to new mechanisms.
As reviewed in much greater length and
detail elsewhere, there have been dozens
of studies implicating T lymphocytes and
other hematopoietic cells in the patho-
genesis of essential hypertension in hu-
mans, and in experimental models of
chronic hypertension. Dating back to the
1960s, Okuda and Grollman induced hy-
pertension in naive rats by passively
transferring lymphocytes harvested from
donor rats rendered hypertensive fol-
lowing experimentally induced renal in-
farction (Okuda and Grollman, 1967).
More recently, a seminal study fromDavid
Harrison’s group reported that Rag1/
mice failed to develop hypertension in
response to chronic exposure to angio-
tensin II, a standard laboratory model of
chronic hypertension in rodents (Guzik
et al., 2007). Passive transfer of T cells,but not B cells, restored the hypertensive
response to angiotensin II infusion. A ma-
jor question is what factor(s) activates
T cells to mediate hypertension?
In this issue of Immunity, Carnevale et al.
(2014) observed that placental growth fac-
tor (PlGF)-deficient mice are protected
against hypertension during angiotensin II
infusion. PlGF, a member of the angiogen-
esis family of factors related to vascular
endothelial growth factor (VEGF), is ex-
pressed by cells from the immune and
cardiovascular systems, but whether it
contributed to T cell activation in hyperten-
sion was previously unknown. PlGF-defi-
cient animals were also protected against
T cell mediated inflammation and tissue
injury in the heart, kidney, and aorta that
occurs following angiotensin II infusion.
Surprisingly, the spleen is the reservoir of
these pathogenic T cells. Release of these
cells from spleen during angiotensin II
infusion is controlled by adrenergic neural
signals to spleen that converge on PlGF.
Angiotensin II infusion increased the
expression of tyrosine hydroxylase, the
rate-limiting enzyme in the biosynthesis
of norepinephrine by adrenergic neurons,
and norepinephrine levels in spleen. Abla-
tion of the adrenergic splenic nerve by sur-
gical removal of the celiac ganglion pre-
vented recruitment of pathogenic T cells
from the spleen to the aorta and kidney.
Similar protection against hypertensionovember 20, 2014 ª2014 Elsevier Inc. 673
